Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 6,604 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Major Depressive Disorder
Interventions: Agomelatine (AGO178C), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 47
States / cities: Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more

Conditions: Osteoarthritis
Interventions: Buprenorphine transdermal delivery system; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1999
U.S. locations: 10
States / cities: Huntsville, Alabama • Phoenix, Arizona • Westminster, Colorado + 6 more

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Melphalan/HDS, Sorafenib; Device · Drug
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Tampa, Florida • New York, New York

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Amisodin, Placebo; Drug · Other
Lead sponsor: PRG Science & Technology Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: KRAS Gene Mutation
Interventions: TVB-2640; Drug
Lead sponsor: David E Gerber; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Cincinnati, Ohio • Dallas, Texas

Conditions: Atrial Fibrillation
Interventions: Ablation; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: South Bend, Indiana • Boston, Massachusetts

Conditions: Tendinopathy
Interventions: SM04755, Vehicle; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Osteoarthritis
Interventions: Cementless Total Knee Arthroplasty; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 10
States / cities: Denver, Colorado • DeLand, Florida • Lebanon, New Hampshire + 7 more

Conditions: Constipation, Parkinson Disease
Interventions: Active Investigational Treatment ENT-01, Placebo Treatment; Drug
Lead sponsor: Enterin Inc.; Industry
Eligibility: 30 Years to 90 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 51
States / cities: Sun City, Arizona • Little Rock, Arkansas • Fountain Valley, California + 44 more

Conditions: Acne Vulgaris
Interventions: IDP-120 Gel, IDP-120 Vehicle Gel; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 585 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 18
States / cities: Rogers, Arkansas • Manhattan Beach, California • San Diego, California + 13 more

Conditions: Arthroplasty, Replacement, Knee
Interventions: CORI™ KNEE TENSIONER; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: New York, New York • New Albany, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Myasthenia Gravis, Generalized
Interventions: IGIV-C, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more

Conditions: Obstructive Defecation Syndrome, Chronic Constipation, Rectocele, Intussusception
Interventions: Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler; Procedure
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 7
States / cities: Orlando, Florida • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: X-Linked Retinitis Pigmentosa
Interventions: AAV5-RPGR; Genetic
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Geographic Atrophy
Interventions: Sirolimus, Lidocaine; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 55 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 13
States / cities: Loma Linda, California • Sacramento, California • Jacksonville, Florida + 10 more

Conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type 3
Interventions: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care, One time survey; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 7 more

Conditions: Achromatopsia
Interventions: adeno-associated virus vector AAV- CNGA3; Biological
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 3 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: ADHD
Interventions: Vyvanse (lisdexamfetamine dimesylate), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 9
States / cities: Little Rock, Arkansas • Irvine, California • Wildomar, California + 5 more

Conditions: Osteoarthritis
Interventions: Oral Salmon Calcitonin, Oral Salmon Calcitonin (Placebo); Drug
Lead sponsor: Nordic Bioscience A/S; Industry
Eligibility: 51 Years to 80 Years
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Tuscaloosa, Alabama • Sacramento, California • Chicago, Illinois + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin degludec, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more

Conditions: Prostate Cancer
Interventions: Saruparib (AZD5305), Darolutamide, No Treatment; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Detroit, Michigan • Providence, Rhode Island

Conditions: Metastasis From Malignant Tumor of Prostate
Interventions: 177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide; Drug
Lead sponsor: Curium US LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 37
States / cities: Tucson, Arizona • Fullerton, California • Long Beach, California + 28 more

Conditions: Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency
Interventions: Hectorol (doxercalciferol capsules), 0.5mcg; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Phoenix, Arizona • Alhambra, California • Riverside, California + 14 more

Conditions: End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
Interventions: BAY1213790 (Osocimab), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 704 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Azusa, California • Brawley, California • Encino, California + 21 more

Search by objective public record fields.

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Low Fluoroscopy Afib Ablation Registry

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

14022 ATTUNE Cementless RP Clinical Performance Evaluation

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Participants With Acne Vulgaris

To Evaluate the Performance of the CORI™ KNEE TENSIONER as an Accessory to the CORI™ Surgical System.

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy

Spinraza in Adult Spinal Muscular Atrophy

Gene Therapy for Achromatopsia (CNGA3)

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis